78
Participants
Start Date
June 1, 2022
Primary Completion Date
August 31, 2026
Study Completion Date
December 31, 2026
AB8939
Intravenous injection (from an initial dose of 0.9 mg/m²)
Venetoclax
the recommended starting dose for AML indication is 100 mg. Dose escalating regimen as per SmPC.
NOT_YET_RECRUITING
MD Anderson Cancer Center, Houston
NOT_YET_RECRUITING
Institut Paoli Calmettes, Marseille
RECRUITING
National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit, Athens
RECRUITING
General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante), Alicante
RECRUITING
Hospital San Pedro de Alcantara, Cáceres
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Hospital Universitario Quirónsalud, Madrid
RECRUITING
MD Anderson Cancer Center Madrid, Madrid
RECRUITING
Clínica Universidad de Navarra, Pamplona
RECRUITING
Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío), Seville
Lead Sponsor
AB Science
INDUSTRY